Dry eye syndrome is a clinical condition wherein the patient experiences ocular and conjunctival irritation due to decreased tear production and/or excessive tear evaporation.
It is associated with increased osmolarity of the tear film and inflammation of the ocular surface.
Goal of treatments are to relieve symptoms of patients, to improve visual acuity & quality of life of patients, to restore ocular surface & tear film to normal homeostatic state and to correct the underlying defect.
Fiscella RG. Understanding dry eye disease: a managed care perspective. Am J Manag Care. 2011 Dec;17(Suppl 16):S432-A439. Accessed 23 Jan 2012. PMID: 22435675
Jackson WB. Management of dysfunctional tear syndrome: a Canadian consensus. Can J Ophthamol. 2009 Aug;44(4):385-394. doi: 10.3129/i09-015. Accessed 23 Jan 2012. PMID: 19606158
International Dry Eye Committee. 2007 report of the International Dry Eye Workshop (DEWS). Ocul Surf. 2007 Apr;5(2):75-92. Accessed 23 Jan 2012. PMID: 17508116
Perry HD. Dry eye disease: pathophysiology, classification, and diagnosis. Am J Manag Care. 2008 Apr;14(3 Suppl):S79-S87. PMID: 18452371
American Academy of Ophthalmology Cornea/External Disease Panel. Preferred practice pattern guidelines. Dry eye syndrome. San Francisco, CA: American Academy of Ophthalmology. http://one.aao.org/. 2013. Accessed 23 Jan 2012.
Children who are fully vaccinated against the flu, ie, receive the recommended number of influenza vaccine doses, have a lower risk of acquiring influenza compared with those who are partially vaccinated, a US study found.
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.